<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02120196</url>
  </required_header>
  <id_info>
    <org_study_id>Asem Ahmed Elfert</org_study_id>
    <nct_id>NCT02120196</nct_id>
  </id_info>
  <brief_title>Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis</brief_title>
  <acronym>SBP</acronym>
  <official_title>Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sherief Abd-Elsalam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the effectiveness of rifaximin versus norfloxacin for
      secondary prevention of spontaneous bacterial peritonitis in patients with liver cirrhosis
      and ascites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be carried out on 100 patients with liver cirrhosis and ascites who will be
      enrolled from Tanta University, Tropical Medicine Department in the period between January
      2014 to 6 months. The selected patients will be randomly assigned to receive 400 mg of
      norfloxacin daily or 1200 mg of rifaximin daily and will be classified into two groups :

      Group 1 : 50 patients will be treated with 1200 mg of rifaximin daily. Group 2 : 50 patients
      will be treated with 400 mg of norfloxacin daily.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with recurrence of SBP</measure>
    <time_frame>6 months</time_frame>
    <description>The total number of paper of participitants with recurrence of SBP</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Spontaneous Bacterial Peritonitis</condition>
  <condition>Ascites</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>rifaximin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1: 109 patients will be treated with 1200 mg of rifaximin daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>norfloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2: 109 patients will be treated with 400 mg of norfloxacin daily for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>rifaximin 1200 mg daily versus norfloxacin 400 mg once daily</description>
    <arm_group_label>rifaximin</arm_group_label>
    <other_name>Gastrobiotic, Trencedia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norfloxacin</intervention_name>
    <description>FDA approved:400mg once daily</description>
    <arm_group_label>norfloxacin</arm_group_label>
    <other_name>Epinor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previous episode of SBP

          -  Total protein in the ascitic fluid below or equal to 1.5 g/dL

        Exclusion Criteria:

          -  Allergy to quinolones

          -  Antibiotic therapy in the 2 weeks preceding inclusion

          -  Recent ( within the previous 2 weeks) episode of digestive hemorrhage

          -  Hepatocellular carcinoma or other neoplasias able to shorten life expectancy

          -  Pregnant and lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asem A Elfert</last_name>
    <role>Principal Investigator</role>
    <affiliation>TUH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherief M. Abd-Elsalam, Lecturer</last_name>
    <phone>00201000040794</phone>
    <email>Sheif_tropical@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tanta university hospital</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherief Abd-Elsalam</last_name>
      <phone>00201000040794</phone>
      <email>Sherif_tropical@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2014</study_first_submitted>
  <study_first_submitted_qc>April 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2014</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sherief Abd-Elsalam</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
    <mesh_term>Norfloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

